Discover the full directors' dealings record of 에이프릴바이오, a listed issuer based in South Korea. Shares are quoted on KR KR, under the authority of DART (FSS). Operating in the Healthcare sector, 에이프릴바이오 has logged 1 public disclosures. Market capitalisation: €1,224.3bn. The latest transaction was filed on 10 March 2026 — Other. Among the most active insiders: 에이프릴바이오. Every trade is accessible without an account.